drugset
drugset / Trial / NCT04193098

Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC

NCT04193098 ↗

Phase 1 Unknown 10 enrolled Tianjin Medical University Cancer Institute and Hospital
NaSingle-groupOpen-labelTreatment

Summary

This prospective, unicentric, open-labe phase I study is to evaluate the safety and effect of autologous cytotoxic T lymphocyte immunotherapy combination with PD-1 inhibitor in the second-line treatment of stage IIIB/IIIC/IV non-small cell lung cancer.

Timeline

Start
2019-06-01
Primary completion
2021-06-01
Completion
2021-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject CTL Cell therapy 1e+09 cells Intravenous
Subject Toripalimab Monoclonal antibody 240 mg Intravenous

Indications

non-small cell lung carcinoma